Open in Screener

RAPP

Rapport Therapeutics Inc

Oct 07 • 09:42AM ET

27.66

-0.08 -0.29 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BLUE REGN SAGE NBIX ACAD MRNA CRSP EDIT

| Held by: VTI IWM IWN IBB SCHA VXF VTWO IWC AVSC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.46	Insider Own	51.98%	Shs Outstand	36.50M	Perf Week	-6.87%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-3.92	Insider Trans	-0.28%	Shs Float	22.14M	Perf Month	-12.11%
Enterprise Value	1.03B	PEG	-	EPS next Q	-0.78	Inst Own	47.31%	Short Float	14.27%	Perf Quarter	97.43%
Income	-88.31M	P/S	-	EPS this Y	20.07%	Inst Trans	0.76%	Short Ratio	4.50	Perf Half Y	190.85%
Sales	0.00M	P/B	3.83	EPS next Y	-29.70%	ROA	-27.96%	Short Interest	3.16M	Perf YTD	55.92%
Book/sh	7.22	P/C	4.90	EPS next 5Y	-7.61%	ROE	-29.42%	52W High	42.27 -34.56%	Perf Year	50.82%
Cash/sh	5.65	P/FCF	-	EPS past 3/5Y	-171.13% -	ROIC	-32.28%	52W Low	6.43 330.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.18% 11.02%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.75	EPS Q/Q	-52.24%	SMA20	4.30%	Beta	1.75	Target Price	51.71
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	36.83%	Rel Volume	0.09	Prev Close	27.74
Employees	69	LT Debt/Eq	0.04	Earnings	Aug 07 BMO	SMA200	91.72%	Avg Volume	701.83K	Price	27.66
IPO	Jun 07, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.90% -	Trades		Volume	4,735	Change	-0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-25	Initiated	Truist	Buy	$44
Aug-06-25	Initiated	H.C. Wainwright	Buy	$31
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Sep-30-25 11:49AM	JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success (Insider Monkey) +6.19%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 04:05PM	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
Sep-09-25 09:17PM	Rapport Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.93% -20.09%
Sep-08-25 04:08PM	Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily) +119.15%
04:05PM	Loading…
04:05PM	Rapport Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:45AM	Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily)
09:28AM	Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year (Benzinga)
06:00AM	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures (GlobeNewswire)
Sep-05-25 04:05PM	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 (GlobeNewswire) -6.45%
Aug-13-25 08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
Aug-07-25 07:00AM	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update (GlobeNewswire) +5.48%
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
07:00AM	Loading…
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	40,835	1,074,725	585,412	Sep 19 04:05 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	35,585	936,472	46,144	Sep 19 04:05 PM
ABRAHAM CEESAY	Director	Sep 17 '25	Proposed Sale	26.19	52,501	1,375,001		Sep 17 04:28 PM
THE DOROTHY CEESAY IRREV TRUST	Director	Sep 17 '25	Proposed Sale	26.19	45,751	1,198,219		Sep 17 04:26 PM
Bredt David	Chief Scientific Officer	Sep 15 '25	Sale	24.19	8,500	205,649	418,142	Sep 17 04:15 PM
Huber Reid M	Director	Sep 12 '25	Buy	24.48	20,400	499,374	20,400	Sep 15 04:05 PM
PAUL STEVEN M	Director	Sep 12 '25	Buy	24.65	41,666	1,027,111	41,666	Sep 15 04:05 PM
Young Wendy B.	Director	Sep 11 '25	Buy	22.60	3,500	79,100	9,500	Sep 11 06:13 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Option Exercise	1.80	5,000	9,000	176,928	Sep 10 04:15 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Sale	38.33	5,000	191,650	171,928	Sep 10 04:15 PM
CHERYL GAULT	Officer	Sep 08 '25	Proposed Sale	14.36	10,000	143,600		Sep 08 04:24 PM
Bredt David	Chief Scientific Officer	Aug 15 '25	Sale	15.00	8,500	127,466	426,642	Aug 18 05:14 PM
Bredt David	Chief Scientific Officer	Jul 15 '25	Sale	14.00	8,500	118,962	435,142	Jul 16 04:14 PM
Bredt David	Chief Scientific Officer	Jun 16 '25	Sale	11.00	8,500	93,522	443,642	Jun 18 04:15 PM
DAVID BREDT	Officer	Jun 16 '25	Proposed Sale	11.19	34,000	380,460		Jun 16 04:24 PM
Bredt David	Chief Scientific Officer	May 15 '25	Sale	9.56	8,500	81,262	452,142	May 19 04:30 PM
Bredt David	Chief Scientific Officer	Apr 15 '25	Sale	9.57	8,500	81,310	460,642	Apr 16 05:00 PM
Bredt David	Chief Scientific Officer	Mar 14 '25	Sale	10.85	8,500	92,205	469,142	Mar 17 05:00 PM
DAVID BREDT	Officer	Mar 14 '25	Proposed Sale	10.02	25,500	255,510		Mar 14 04:20 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 12 '25	Buy	10.10	9,900	99,990	9,900	Mar 13 05:13 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 13 '25	Buy	9.98	100	998	10,000	Mar 13 05:13 PM
Young Wendy B.	Director	Mar 12 '25	Buy	10.21	6,000	61,250	6,000	Mar 13 05:00 PM

PCRX Pacira BioSciences Inc daily Stock Chart

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR VTI VB IWM AVUV VBR VXF IJS SPSM IWN

Index	RUT	P/E	-	EPS (ttm)	-2.79	Insider Own	2.74%	Shs Outstand	44.90M	Perf Week	-7.26%
Market Cap	1.07B	Forward P/E	7.33	EPS next Y	3.26	Insider Trans	-2.16%	Shs Float	43.70M	Perf Month	-10.62%
Enterprise Value	1.26B	PEG	-	EPS next Q	0.65	Inst Own	116.01%	Short Float	15.30%	Perf Quarter	3.15%
Income	-127.46M	P/S	1.52	EPS this Y	-10.36%	Inst Trans	1.63%	Short Ratio	10.35	Perf Half Y	4.32%
Sales	705.85M	P/B	1.42	EPS next Y	13.73%	ROA	-8.01%	Short Interest	6.69M	Perf YTD	26.86%
Book/sh	16.88	P/C	2.41	EPS next 5Y	5.43%	ROE	-15.57%	52W High	27.64 -13.53%	Perf Year	50.41%
Cash/sh	9.92	P/FCF	9.17	EPS past 3/5Y	- -51.99%	ROIC	-10.83%	52W Low	15.16 57.65%	Perf 3Y	-55.07%
Dividend Est.	-	EV/EBITDA	8.20	Sales past 3/5Y	8.98% 10.73%	Gross Margin	70.08%	Volatility	4.18% 3.49%	Perf 5Y	-60.25%
Dividend TTM	-	EV/Sales	1.78	EPS Y/Y TTM	-301.59%	Oper. Margin	9.01%	ATR (14)	0.86	Perf 10Y	-41.64%
Dividend Ex-Date	-	Quick Ratio	1.91	Sales Y/Y TTM	2.25%	Profit Margin	-18.06%	RSI (14)	33.93	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.38	EPS Q/Q	-127.42%	SMA20	-7.49%	Beta	0.37	Target Price	29.00
Payout	-	Debt/Eq	0.83	Sales Q/Q	1.73%	SMA50	-5.37%	Rel Volume	0.32	Prev Close	23.87
Employees	790	LT Debt/Eq	0.55	Earnings	Aug 05 AMC	SMA200	-1.79%	Avg Volume	645.90K	Price	23.90
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.23% -1.08%	Trades		Volume	16,215	Change	0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75

Show Previous Ratings

Oct-03-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-25 06:04PM	Hanesbrands, Rogers, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-25 03:27AM	Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... (GuruFocus.com)
Aug-05-25 08:00PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings (Zacks)
05:35PM	Loading…
05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
04:35PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:45AM	What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 12:12PM	PharmaCorp Announces Filing of Annual Information Form (GlobeNewswire)
Jul-24-25 08:00AM	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 (GlobeNewswire)
Jul-22-25 08:00AM	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts (GlobeNewswire)
Jul-16-25 08:40AM	Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Jul-10-25 11:41AM	Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement (Insider Monkey)
Jul-03-25 04:01PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:06AM	Loading…
Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Loading…
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%
08:15AM	DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders (PR Newswire)
Apr-17-25 05:00PM	Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders (GlobeNewswire)
Apr-15-25 01:45PM	Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -8.32%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
10:03AM	Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act (Seeking Alpha)
09:41AM	Pacira price target raised to $28 from $25 at Truist (TipRanks)
05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks) +14.67%
Apr-07-25 04:30PM	Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 08:00AM	Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 12:39PM	Pacira Surges 66.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 04:05PM	Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual (GlobeNewswire)
08:25AM	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences (PR Newswire)
Mar-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 07:00AM	Bull of the Day: Pacira BioSciences (PCRX) (Zacks)
Mar-02-25 12:27PM	Is Pacira BioSciences, Inc. (PCRX) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 10:09AM	Q4 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.24%
02:36AM	Pacira BioSciences Inc (PCRX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-27-25 05:26PM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
04:00PM	Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio (GlobeNewswire)
Feb-26-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March (GlobeNewswire)
07:46AM	What To Expect From Pacira BioSciences Inc (PCRX) Q4 2024 Earnings (GuruFocus.com)
Feb-20-25 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
08:00AM	Pacira to Report 2024 Financial Results on Thursday February 27, 2025 (GlobeNewswire)
Feb-14-25 05:45AM	Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Feb-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 09:55AM	Should You Buy Pacira (PCRX) After Golden Cross? (Zacks)
Jan-31-25 05:45AM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Jan-30-25 08:00AM	Pacira Announces Updates to Board of Directors (GlobeNewswire)
Jan-21-25 08:00AM	Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments (GlobeNewswire)
Jan-16-25 01:56PM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights PCRX (GlobeNewswire)
Jan-10-25 08:00AM	Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization (GlobeNewswire) +11.09%
Jan-07-25 11:49AM	Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain (Benzinga)
08:00AM	Pacira BioSciences Receives FDA 510k Clearance for New iovera SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block (GlobeNewswire)
Jan-02-25 04:01PM	Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 09:50AM	Here's Why Pacira (PCRX) is a Strong Momentum Stock (Zacks)
Dec-11-24 08:05AM	DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
Dec-06-24 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-03-24 07:30AM	Pacira Awarded New U.S. Patent Covering EXPAREL Composition (GlobeNewswire) -6.34%
Nov-29-24 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-14-24 10:05AM	Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
Nov-12-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-07-24 08:49AM	Q3 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:20AM	Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Nov-06-24 04:10PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 07:55AM	Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.05%
Nov-04-24 08:00AM	Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Director	Sep 04 '25	Sale	27.19	2,354	64,005	9,039	Sep 08 05:37 PM
Ceesay Abraham	Director	Sep 04 '25	Proposed Sale	27.19	2,354	64,005		Sep 04 09:40 AM
BIGAL MARCELO	Director	Aug 07 '25	Sale	23.67	4,912	116,267	11,393	Aug 11 04:09 PM
BIGAL MARCELO	Director	Aug 07 '25	Proposed Sale	23.67	4,912	116,279		Aug 07 03:17 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM
GAUGLER DARYL	Officer	Mar 06 '25	Proposed Sale	23.25	500	11,625		Mar 06 12:06 PM
SLONIN JONATHAN	Chief Medical Officer	Jan 06 '25	Sale	18.40	879	16,174	93,444	Jan 06 06:23 PM
SLONIN JONATHAN	Officer	Jan 06 '25	Proposed Sale	18.40	879	16,174		Jan 06 11:11 AM
GAUGLER DARYL	Chief Operating Officer	Dec 13 '24	Sale	19.76	500	9,880	115,200	Dec 16 04:13 PM
GAUGLER DARYL	Officer	Dec 13 '24	Proposed Sale	19.76	500	9,880		Dec 13 09:41 AM

RAPP

Rapport Therapeutics Inc

PCRX

Pacira BioSciences Inc

Upgrade your FINVIZ experience